Exogems is a Swiss biotech company focused on harnessing the therapeutic potential of exosomes derived from adipose tissue. Central to their approach is the Lipogems® technology, a unique medical device that facilitates the closed-loop processing and transfer of autologous adipose tissue in a single surgical step. This device is notable for its ability to preserve the Mesenchymal Stem Cells (MSC) within the fat, which remain in their natural niche, enhancing their regenerative capabilities. By leveraging this technology, Exogems aims to produce highly efficacious exosomes that can significantly impact the fields of inflammation and regenerative medicine.

The company combines its innovative Lipogems® platform with established biopharmaceutical manufacturing practices to ensure scalable and cost-effective production of exosomes. This strategic integration is designed to enable consistent and reliable therapeutic outcomes, positioning Exogems at the forefront of advancements in regenerative therapies. With a leadership team that includes experts in stem cell research and regenerative medicine, Exogems is committed to advancing the understanding and application of exosome therapies in clinical settings.

Switzerland

Exogems uses an FDA-approved medical device (Lipogems®) to produce exosomes from the mesenchymal stems cells in fat. They are developing methods for using these exosomes to deliver therapeutics.

Exogems

Company Details